Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Drugs in Development
Details:
(CVL006) is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): CVL006,Pemetrexed,Carboplatin,Sacituzumab Tirumotecan,DS-8201,Enfortumab Vedotin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2025
Lead Product(s) : CVL006,Pemetrexed,Carboplatin,Sacituzumab Tirumotecan,DS-8201,Enfortumab Vedotin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CVL006 Combination Therapy in Advanced Solid Tumors
Details : (CVL006) is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 05, 2025
Details:
CVL006 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): CVL006
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 01, 2024
Clinical Study of CVL006 Injection in Advanced Solid Tumors
Details : CVL006 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 01, 2024
Details:
Neratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): Neratinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 25, 2024
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Details : Neratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2024
Details:
Neratinib Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastroesophageal Junction Neoplasms.
Lead Product(s): Neratinib,Capecitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 19, 2024
Lead Product(s) : Neratinib,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Neratinib Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastroesophageal Junction Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2024
Details:
CVL237 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of PI3K/P110 delta Hyperactivation Syndrome.
Lead Product(s): CVL237
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2024
Lead Product(s) : CVL237
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CVL237 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of PI3K/P110 delta Hyperactivation Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 05, 2024
Details:
CVL237 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): CVL237
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 27, 2023
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Details : CVL237 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 27, 2023
Details:
Neratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Neratinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 08, 2023
Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
Details : Neratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
